If “[s]equencing alone cannot determine whether transmission has been continuous or sustained,” how much of modern outbreak science is proven reality—and how much is interpretation?
A new ProPublica investigation into purported measles outbreaks in Texas and Utah contains a quietly devastating admission from the Centers for Disease Control and Prevention (CDC) about the limits of modern genomic outbreak surveillance.
ProPublica had asked the CDC whether it had linked any of Utah’s measles cases to an international outbreak.
“Sequencing alone cannot determine whether transmission has been continuous or sustained,” the agency told ProPublica.
In plain English:
Even if two purported measles genomes appear almost identical computationally, the sequencing data itself cannot independently prove the virus spread continuously from person to person across states and over time.
That distinction is important because modern outbreak systems increasingly rely on a narrative of:
genomic sequencing,
phylogenetic “family trees,”
mutation tracking,
lineage reconstruction,
and computational epidemiology
to support claims that outbreaks are connected, transmission is ongoing, and diseases have become “endemic.”
These same systems were heavily used during COVID to justify lockdowns, vaccine mandates, school closures, quarantine powers, travel restrictions, and other unprecedented government response measures.
How much of modern outbreak science is proven reality—and how much is computer interpretation?
If even CDC admits these genomic systems cannot independently prove continuous real-world transmission, the public may need to reconsider how much trust should be placed in media headlines, “variant” narratives, endemicity claims, and government emergency measures built on computer sequence-based outbreak interpretation systems. (SEE link for article)
CDC Officials Involuntarily Quarantine Americans After Hantavirus Outbreak on Cruise Ship
by Carolyn Hendler, JD
Published June 10, 2026
Officials at the U.S. Centers for Disease Control and Prevention (CDC) issued mandatory federal quarantine orders to 18 American citizens who had been passengers aboard the M/V Hondius, an expedition cruise ship on which there was an outbreak of the deadly Andes strain of hantavirus. None of the 18 Americans had tested positive for the respiratory virus at the time the involuntary quarantine orders were issued.1
The orders required the Americans to be sent to and remain in the federally funded National Quarantine Unit (NQU) at the University of Nebraska Medical Center in Omaha, Nebraska, through at least May 31, 2026. Dr. Jay Bhattacharya, who leads both the CDC and the U.S. National Institutes of Health (NIH) signed the quarantine orders. Bhattacharya is a co-author of the Great Barrington Declaration, which was written to protest the government’s lockdown policies in response to the COVID-19 pandemic.2
Several passengers who had been on the cruise ship had already made arrangements with their state and local health departments to be monitored at home. However, all 18 passengers were informed at the last minute that they would not be allowed to return home and instead would be forced to stay in the NQU.3
Angela Perryman, 47, was among the 18 Americans ordered to remain in quarantine at the Nebraska facility.4 Despite federal health officials publicly stating that the passengers’ stay at NQU was entirely voluntary, when Perryman and another passenger attempted to leave, they were handed federal stay-in-place quarantine orders.5 Anyone violating the quarantine orders issued by the government would face a criminal fine or up to one year in jail.6
Perryman told NPR:
I am angry. I feel betrayed because I’m being imprisoned. It’s a nice prison. But this is a prison. Let’s be clear: I am being detained against my will.7
The U.S. government has been funding gain-of-function hantavirus experiments since at least 2017.
A July 2025 Pathogens publication confirms the U.S. military funded experiments aerosolizing hantavirus pathogens (making them airborne) with a 30% fatality rate.
Less than a year after the publication, the Andes hantavirus cruise ship outbreak would be declared.
Moreover, NIAID’s $70 million PROVIDENT program actively funded and operated a large-scale hantavirus preparedness initiative that engineered vaccine platforms, mapped Andes hantavirus structures in unprecedented detail, developed rapid-response countermeasure systems, and prioritized hantaviruses as future pandemic targets in the run-up to the 2026 international Andes hantavirus outbreak.
The Andes hantavirus genome was built from human blood at the infamous U.S. military biolab Fort Detrick.
Recent genetic analysis finds that hantavirus PCR test sequences—used to count cases—also match human DNA, raising concerns that the test is mistaking human genetic material for hantavirus.
The government’s hantavirus research, surveillance, genome-construction, and countermeasure infrastructure was already fully operational before the 2026 outbreak narrative emerged.
Kennedy has now invoked federal liability protections for favipiravir that is not approved anywhere in the world for hantavirus treatment and was only conditionally authorized in Japan for pandemic influenza—yet is now being positioned for use on Americans.
Preclinical animal studies have shown that favipiravir has the risk of teratogenicity and reproductive toxicity in experimental animals, including findings indicative of birth defects in mice, rats, rabbits, and monkeys, along with decreases in live fetal body weight and in the number of live fetuses.
It is being sold across the wellness world as a daily brain booster. Meanwhile, the green pigment in your salad and the blue pigment in spirulina do the same thing — safer, with better evidence, and as the way your body was designed to harvest sunlight in the first place.
Scroll through wellness Substacks, biohacker podcasts, or longevity posts on X in 2026 and you cannot miss methylene blue. A tiny dropper bottle of deep navy liquid. A blue-tongued grin. Claims that it “supercharges mitochondria,” “uncloggs neurons,” and turns aging brains young again.
It is one of the strangest stories in the modern wellness movement.
Because methylene blue is not a botanical, not a peptide, not a mushroom extract. It is a synthetic phenothiazine dye, invented in 1876 by a German chemist named Heinrich Caro to color cotton and wool. It has been used to stain microscope slides, to disinfect aquariums, to treat malaria when nothing else was available in the 19th century, and — in modern emergency rooms — as an acute antidote for a rare blood disorder called methemoglobinemia.
It was never designed as a daily supplement. And once you look at what the toxicology literature actually says — the kind of literature that the FDA’s own regulators read before approving a new drug — the case for taking methylene blue as a nootropic falls apart.
Worse, it falls apart precisely because there is a better, safer, evolutionarily older molecule doing the same job in your mitochondria — and it is sitting in your refrigerator.
This is the story of how a textile dye got mistaken for a mitochondrial medicine, and why the chlorophyll in your spinach and the phycocyanin in spirulina are doing what methylene blue claims to do, without the genotoxicity.
(See link for article)
__________________
**Comment**
Many are promoting MB, including LLMDs for Lyme/MSIDS. This is another take on it to consider. The article also lists other substances that do similar things but are completely safe.
Methylene blue is not a miraculous new discovery. It’s the opposite. Created in 1876 in a lab, it is the oldest manmade chemical to be used in medicine. But for well over a century, methylene blue has never been FDA-approved for psychiatric purposes. Later, its chemical structure was modified in labs to create many of the earliest, most neurotoxic psychiatric drugs. (See link for the in-depth article by psychiatrist Peter Breggin who has decades of experience and who has written many scientific papers and books showing how human beings who take psychiatric drugs sometimes are initially stimulated when the drug over-activates the monoamine neurotransmitters, including epinephrine, norepinephrine, serotonin, and dopamine; but eventually, similar to the animals, the human drug recipients typically become more subdued, apathetic, or disengaged from their own feelings, those around them, and with life itself. Breggin does not prescribe psychiatric drugs as a treatment as he feels they do more harm than good. Instead he offers therapy, and education on more effective and healthier principles of living. He is the author of the only medical textbook on the subject, called “Psychiatric Drug Withdrawal: A Guide for Prescribers, Therapists, Patients and Their Families.”)
COVID forced the public to ask whether a pandemic could come from a lab. Now, years later, Congress is hearing testimony about a COVID lab-leak coverup, and Tulsi Gabbard is reportedly investigating more than 120 U.S.-funded foreign biolabs.
Experts Warn Lab Leaks ‘Surprisingly Common’ After NIH Confirms Possible Exposure to Deadly Virus at Montana Lab
An employee at Rocky Mountain Laboratories in Montana was potentially exposed to Crimean-Congo hemorrhagic fever following a personal protective equipment breach in November 2025, according to the National Institutes of Health. The incident highlights the lack of a centralized federal system to track all laboratory incidents across agencies and institutions.
This article was originally published by The Defender — Children’s Health Defense’s News & Views Website.
A Rocky Mountain Laboratories employee in Hamilton, Montana, may have been exposed to Crimean-Congo hemorrhagic fever (CCHF) in November 2025 after an accidental breach of personal protective equipment, according to the National Institutes of Health (NIH).
The incident was reported to NIH in February 2026, according to internal communications referenced in documents shared by White Coat Waste.
NIH officials said the employee did not become infected, and no transmission occurred.
“The employee was immediately isolated and monitored under appropriate care at a specialized medical facility before it was confirmed that no actual exposure or transmission had occurred,” NIH said in a statement. “At no time was there any risk to the public or to other staff.”
What is Crimean-Congo hemorrhagic fever?
CCHF is a rare but potentially fatal viral disease spread primarily through infected tick bites or contact with the blood and bodily fluids of infected animals or people, according to the Centers for Disease Control and Prevention (CDC).
The disease, which is most common in parts of Africa, Asia, the Middle East and Eastern and Southern Europe, can cause high fever, severe headache, vomiting, internal bleeding and hemorrhaging. The CDC reported that up to 50% of hospitalized patients may die from the illness.
The Food and Agriculture Organization of the United Nations said veterinarians and healthcare workers, and people who work closely with livestock, face an elevated risk of infection, while human-to-human transmission can occur through exposure to contaminated blood, medical equipment or bodily fluids.
There is no approved cure or available vaccine for CCHF, according to the World Health Organization.
Incident occurred at high-containment NIH lab
Rocky Mountain Laboratories, a Biosafety Level 4 (BSL-4) facility operated by NIH, conducts research on high-consequence infectious diseases, including tick-borne and emerging viral pathogens.
The facility is designed to study “confounding health issues, such as coronavirus, influenza, prion diseases, and antibiotic-resistant bacteria.”
It is part of the National Institute of Allergy and Infectious Diseases. It has historically focused on vector-borne and infectious conditions, including Lyme disease, Rocky Mountain spotted fever and other pathogens.
Lab leaks ‘surprisingly common’
Lab leaks involving dangerous pathogens occur more often than widely understood, according to some biosafety researchers.
Richard Ebright, Ph.D., a molecular biologist at Rutgers University in New Brunswick, New Jersey, said lab accidents that result in laboratory-acquired infections or releases are “surprisingly common.”
“The CCHF incident … was just one of an average of five such events that occur every week in the U.S., Canada and the U.K.,” he said.
Dr. William Schaffner, an infectious disease specialist and professor at Vanderbilt University Medical Center in Nashville, Tennessee, said these types of dangers are treated with vigilance.
“When there is a leak there is a response,” he said. “The general track record is an affirmation that this system is working around the world.”
‘Not mandatory’ to report all leaks
Oversight of high-containment biological research laboratories in the U.S., however, remains fragmented, without a centralized federal system to track all laboratory incidents across agencies and institutions.
“There is no national database because it’s not mandatory to report all leaks,” said Alina Chan, Ph.D., a vector and genetic engineering specialist.
However, reporting of accidents, exposures and potential containment breaches in the U.S. has “no federal accounting of incidents” beyond a narrow set of regulated pathogens and “no official registry” for many high-containment laboratories.
Korol’s analysis contrasted the U.S. system with Canada’s centralized Laboratory Incident Notification Canada program, which requires mandatory national reporting of biosafety incidents. She warned that inconsistent documentation and oversight can hinder transparency, risk assessment and coordinated responses to potential lab leaks.
‘Continual improvement’ needed
A 2024 scoping review in The Lancet documented 309 lab-acquired infections involving 51 pathogens and 16 reported accidental pathogen escape incidents between 2000 and 2021.
The authors concluded that “continual improvement” in biosafety management and reporting standards is essential, noting that underreporting and inconsistent oversight likely obscure the true scale of the problem.
Researchers said stronger reporting systems and root-cause investigations are necessary to reduce future incidents and improve laboratory accountability worldwide.
The authors wrote that “the question is not if a pathogen will escape, but rather which pathogen will and what measures are in place to contain an escape with serious consequences.”
Baric Published Traceless Coronavirus Genome Engineering Platform Just Days Before the 2002 SARS-CoV-1 Pandemic Began
NIH-funded project describes how to digitally assemble, manipulate, and reconstruct full coronavirus genomes while removing visible engineering fingerprints from the final sequence.
In November 2002—the same month Chinese officials later said the first SARS cases began appearing in Guangdong Province—a team led by University of North Carolina coronavirologist Ralph Baric published a paper describing a programmable, full-length coronavirus genome assembly system capable of reconstructing coronavirus genomes while removing visible assembly fingerprints from the final construct.
The paper, published November 1, 2002, in the Journal of Virology, was titled “Systematic Assembly of a Full-Length Infectious cDNA of Mouse Hepatitis Virus Strain A59” and described a new reverse-genetics platform for assembling an entire coronavirus genome from modular DNA fragments.
The work was financed by American tax dollars in the form of research grants from the National Institutes of Health (NIH): “AI23946 and GM63228 to R.S.B., AI26603 to M.R.D., and AI17418 to S.R.W.”
The timing raises obvious questions about whether the emergence of sophisticated government-backed coronavirus engineering systems and the beginning of the SARS era were truly independent events.
Important excerpt:
Years later, Baric would outline and patent how to engineer coronaviruses with SARS-CoV-2’s defining traits—a furin cleavage site (PRRA) insertion at the S1/S2 junction, targeted human-optimizing mutations throughout the receptor-binding domain (including the critical Q498 residue), and the two-proline (V1060P/L1061P) substitution to stabilize the spike protein in its prefusion conformation—just months before the COVID-19 pandemic began.
(See link for article)
**Comment**
It’s important to update history when facts become known.
The reason it’s important to link Baric’s paper and work done on SARS is because the work led to COVID. It’s important to emphasize the bit about ‘removing visible assembly fingerprints.’ This simply means it was manipulated purposely to be invisible – a lot like Lyme/MSIDS.
Just to refresh your memory, President Trump declared a national emergency in March 2020, which consolidated power into the executive branch, placing COVID as a military operation and effectively declaring a medical martial law. According to Attorney Todd Callender, all federal legal cases regarding COVID crimes were dismissed because the military was prosecuting a war during a declared national emergency. This can happen again at any time.
An HHS-funded study published this month says that scientists have lab-engineered brand-new reassortant “Frankenstein” bird flu viruses said to carry genetic components from the 2024 dairy cow H5N1 outbreak and a purportedly fatal 2025 Washington H5N5 case, creating pathogens the paper warns may possess enhanced immune-evasion potential in humans.
The study, published in Nature Communications, was conducted by researchers from the University of Pennsylvania, Children’s Hospital of Philadelphia, and the University of Chicago.
The paper repeatedly warns that the bird flu constructs like the ones these researchers engineered may pose an increased risk to humans because much of the population possesses weak or nonexistent immunity against them.
The experiments align with published gain-of-function definitions involving enhanced immune evasion, altered host range dynamics, and pandemic-preparedness research.
“This project was funded in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract no. 75N93021C00015 and grant number R01AI08686.”
The disclosure section also states lead author Scott E. Hensley:
“is a co-inventor on patents that describe the use of nucleoside-modified mRNA as a vaccine platform.”
The paper further states Hensley received consulting fees from:
Sanofi
Pfizer
Lumen
Novavax
Merck
(See link for article)
According to investigative journalist Jon Fleetwood, newly released H.R. 8595, which readies $3.35 BILLION for future global health threats, keeps Bill Gates’ ‘vaccine’ syndicate GAVI plugged into the U.S. funding pipeline.
the bill is not merely funding emergency humanitarian aid.
It’s funding the continued buildout of international public health infrastructure capable of coordinating surveillance systems, outbreak-response mechanisms, immunization campaigns, emergency-response networks, and foreign health-crisis operations across multiple nations.
The legislation also explicitly authorizes programs tied to: “disaster preparedness training for health crises” and: “programs to prevent, prepare for, and respond to unanticipated and emerging global health threats.”
Health and Human Services Secretary Robert F. Kennedy Jr. has invoked the controversial PREP Act to shield FUJIFILM Toyama Chemical from legal liability for favipiravir (Avigan), an antiviral drug that is not approved for hantavirus treatment in any country and has never received FDA approval in the United States.
The declaration, signed May 22, 2026, provides broad liability protection to the Japanese manufacturer, distributors, and healthcare providers using the drug on people said to have been exposed during the MV Hondius cruise ship outbreak and their close contacts.
This PREP Act declaration, in effect through July 18, 2026, limits lawsuits for injuries or deaths caused by the drug.
The move raises major health freedom concerns involving informed consent, bodily autonomy, pharmaceutical liability shielding, experimental countermeasure deployment during a publicized outbreak event, and the use of emergency powers to protect manufacturers and administrators from accountability if Americans are injured or killed by the drug.
You can contact HHS here to voice opposition to the use of emergency powers to shield experimental hantavirus countermeasures and pharmaceutical manufacturers from legal liability. (See link for article)
Important Excerpts:
According to the official Japanese regulatory documents from the Pharmaceuticals and Medical Devices Agency (PMDA), preclinical animal studies have shown that favipiravir has the risk of teratogenicity and reproductive toxicity in experimental animals, including findings indicative of birth defects in mice, rats, rabbits, and monkeys, along with decreases in live fetal body weight and in the number of live fetuses.
The official Japanese product label for favipiravir warns that the drug can cause serious hepatic dysfunction and jaundice, including clinically significant elevations in liver enzymes (AST/GOT, ALT/GPT, γ-GTP), which may progress to life-threatening liver injury.
A July 2025 Pathogens publication confirms the U.S. military funded experiments aerosolizing hantavirus pathogens (making them airborne) with a 30% fatality rate.
Less than a year after the publication, the Andes hantavirus cruise ship outbreak would be declared.
Moreover, NIAID’s $70 million PROVIDENT program actively funded and operated a large-scale hantavirus preparedness initiative that engineered vaccine platforms, mapped Andes hantavirus structures in unprecedented detail, developed rapid-response countermeasure systems, and prioritized hantaviruses as future pandemic targets in the run-up to the 2026 international Andes hantavirus outbreak.
The Andes hantavirus genome was built from human blood at the infamous U.S. military biolab Fort Detrick.
Study Finds All Major Pharmaceutical Companies Implicated in Bribery Schemes
by Carolyn Hendler, JD
Published
A study published in February 2026 in the Journal of Law, Medicine & Ethics is the first to compile decades of Organization for Economic Cooperation and Development (OECD) enforcement records into a single analysis. Researchers Kohler, Khan, and Bowra reviewed OECD Working Group on Bribery reports from 1999 through early 2025 and found that virtually every major pharmaceutical company operating globally has been implicated in at least one foreign bribery scheme.1
The underlying cases were drawn from U.S. Department of Justice and Securities and Exchange Commission enforcement actions documented over many years. Together, they reveal a pattern of corruption spanning dozens of countries and totaling more than one billion dollars in penalties.
Pfizer, GlaxoSmithKline, Sanofi Among Vaccine Companies Implicated
The researchers identified 21 investigations involving 19 pharmaceutical companies and numerous subsidiaries across five OECD member nations. The United States accounted for 14 of those investigations, followed by Germany and Denmark with three each, and Greece and Italy with one each.2 Among the companies publicly named were Pfizer, Johnson & Johnson, Novartis, Teva, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Sanofi, Eli Lilly, Novo Nordisk, SciClone, BioTest, and Nordion.3
The study defines bribery as “the offering, promising, giving, accepting or soliciting of an advantage as an inducement for an action which is illegal, unethical or a breach of trust.”4
The authors explain:
… pharmaceutical company bribes and other financial inducements can distort prescribing and compromise regulations that are designed to ensure drug safety and efficacy. More generally, pharmaceutical industry corruption affects patient safety and health care resource allocation worldwide.5
Over One Billion Dollars in Sanctions Paid Out by Companies
The implicated companies paid a combined $1,111,225,911 in sanctions. That total included $586,263,414 in fines, $447,237,274 in returned profits, and $77,545,872 in prejudgment interest.6 Despite the scale of the financial penalties, not one company admitted wrongdoing in any of the 21 cases.7
How the Bribery Schemes Operated
The study found that bribery schemes were not isolated acts by low-level employees acting on their own. Rather, senior executives and regional directors within the drug companies approved and, in some cases, directed the payments. Subsidiaries, shell companies, and third-party vendors were used to route payments and give them the appearance of legitimacy. Twelve of the 19 investigations found that subsidiaries were used specifically to conceal bribery operations. The bribes were used to secure regulatory approvals, influence prescribing patterns, and drive drug sales in markets around the world.8
Bribes Hidden in Distributor Discounts
A second pattern identified in the study involved pharmaceutical companies granting unusually steep discounts to distributors. The distributors then used the excess funds to pay bribes to physicians and government officials. Companies falsely recorded the discounts as legitimate marketing or sales expenses, concealing the payments in their books.
The arrangement had a direct consequence for patients. When physicians received payments tied to a particular drug, their prescribing decisions were driven by financial benefit rather than patient need.10
Novartis Vietnam worked with a distributor that paid bribes directly to healthcare providers and reimbursed up to 50 percent of those costs through credit notes. Teva Mexico funneled cash to physicians through a Copaxone distributor and mislabeled the payments as revenue reductions. Eli Lilly’s Brazilian subsidiary granted discounts of 17 to 19 percent instead of the standard 10 percent, concealing a six percent bribe to state officials within the markup.11
Novartis
Between 2012 and 2015, a Novartis subsidiary in Greece bribed employees at state-owned hospitals and clinics to increase prescriptions for Lucentis, a drug used to treat macular degeneration. Physicians were paid more than $5,000 per event attended. Internal Novartis documents described the arrangement as a return on investment and tied physician payments to their prescription volumes.12
In South Korea, a Novartis subsidiary channeled more than $16.3 million through third-party medical journals as improper payments to physicians. In June 2020, Novartis and its subsidiaries agreed to pay $345 million to resolve Foreign Corrupt Practices Act charges brought by the U.S. Department of Justice (DOJ) and the Securities and Exchange Commission (SEC). Novartis Hellas SACI paid a criminal penalty of $225 million and entered a three-year deferred prosecution agreement.13
Johnson & Johnson
In Greece, Poland, and Romania, Johnson & Johnson subsidiaries and agents used slush funds, sham contracts, and offshore accounts in the Isle of Man to reward physicians and hospital administrators. The drug company was also accused of paying kickbacks in Iraq.
Johnson & Johnson agreed to pay more than $48 million to resolve SEC charges and $21.4 million to resolve parallel DOJ criminal charges. However, the large pharmaceutical company did not admit or deny the allegations.14
Pfizer
Pfizer subsidiaries in Italy and Russia were accused by the SEC in 2012 of paying bribes over approximately a decade to foreign government officials. They paid the bribes in order to secure regulatory and formulary approvals, boost sales, and increase prescriptions.
After voluntarily disclosing the misconduct in 2004, Pfizer agreed to pay $26.3 million to the SEC to resolve the charges. Its subsidiary Pfizer HCP paid a separate $15 million criminal penalty to the DOJ. Like the other big pharmaceutical companies, Pfizer did not admit or deny the allegations.15
Teva
Teva Pharmaceuticals made illicit payments to government officials in Russia, Ukraine, and Mexico to increase market share, according to the U.S. Department of Justice and the SEC. Those payments generated $214 million in illegal profits. Teva agreed to pay $283 million in criminal fines to the DOJ and $236 million in disgorgement and prejudgment interest to the SEC, for a combined total of $519 million.16
GlaxoSmithKline
GlaxoSmithKline’s subsidiary in China was fined CN¥3 billion by Chinese authorities after an investigation found it had bribed physicians to increase drug sales. It was the largest fine imposed by a Chinese court at the time. The Securities and Exchange Commission later resolved Foreign Corrupt Practices Act charges against the company for the same conduct, settling for $20 million.17
AstraZeneca and Sanofi
AstraZeneca paid $5.5 million to the SEC to resolve charges that it made improper payments to government-controlled healthcare providers in China and Russia.18 Sanofi settled Foreign Corrupt Practices Act charges with the SEC for $25.2 million in 2018. The agency found that employees and agents in multiple countries made improper payments to foreign officials, including physicians, between 2011 and 2015.19
Zero Admissions of Wrongdoing
Across all 21 investigations spanning more than two decades of OECD monitoring, no pharmaceutical company admitted any wrongdoing. Companies paid the over one billion dollars in combined penalties and moved forward. The study’s authors concluded that bribery in the pharmaceutical sector is not an isolated event but a systemic and recurring feature of how some of the world’s largest drug companies have operated in markets across the globe.2021
The authors suggest that the wide-spread pattern of bribery across the pharmaceutical industry is indicative of institutional corruption. Both the legal and illegal acts of bribery by big pharma “pervert institution’s function under conditions that may promote personal benefit” and serve to undermine the public.
Governor Bob Ferguson announced this month that Washington State is now part of the World Health Organization Global Outbreak and Response Network (GOARN), an international syndicate of “public health agencies, national governments, academic centers, laboratories, and response organizations focused on rapidly detecting and responding to public health emergencies,” according to a press release from the Washington State Nurses Association (WSNA).
Washington joins California, Illinois, Colorado, and New York City by entering GOARN.
According to WSNA, Washington’s public health leaders will fall in line with the WHO’s:
global outbreak early-warning alerts, meaning real-time surveillance tied into an international detection system
technical collaboration and support during major public health events, meaning coordinated response across jurisdictions
international training, exercises, and best-practice exchanges, meaning standardized response protocols
and coordinated outbreak response support, meaning integrated deployment during declared emergencies.
Congress has already confirmed that the WHO’s response to the COVID-19 pandemic “was an abject failure” and that the WHO’s “newest effort to solve the problems exacerbated by the COVID-19 pandemic — via a “Pandemic Treaty” — may harm the United States.”
This means Washington’s decision comes despite federal findings that the WHO mismanaged the last pandemic and is advancing new agreements that could expand its influence over future responses.
You can contact Gov. Ferguson’s office here to voice your opposition to Washington’s integration into a WHO-linked outbreak surveillance and response system and demand accountability for aligning state public health infrastructure with failed global coordination mechanisms. (See link for article)
____________
**Comment**
Take away: states are bypassing the federal government’s move to remain sovereign and not under the umbrella of unelected globalists like the international WHO; however, it’s all clear as mud as there still remains a legal path for U.S./WHO collaboration due to Congress authorizing up to 60 U.S. Public Health Service employees assigned to work through and with WHO-funded programs, alongside USAID and UNICEF—entities closely integrated with the same global health governance framework.
In global health policy, “child survival activities” is a broad WHO umbrella that routinely includes vaccination campaigns, disease surveillance, outbreak response, and health-system operations, meaning the statute authorizes U.S. personnel to work inside WHO-funded public-health infrastructure—not narrow, child-only care—despite the formal withdrawal.
Congress also enacted legislation allocating at least $5.5 billion in taxpayer funding to finance pandemic and outbreak preparedness in fiscal year 2026—despite no declared pandemic and no formal emergency authorization.
The funding is contained in the Consolidated Appropriations Act, 2026 (H.R. 7148), which Trump signed into law on February 3, 2026, after the bill passed both chambers of Congress and was presented to the White House earlier that day. Source
Influenza is the only purported virus explicitly named in the statute.
All of this should feel like déjà vu to anyone reading this website, because it’s been done before,like a bad movie script that keeps being recycled, and now states are making global tyranny even easier to achieve!
The same architects of the last plandemic are priming the world for the next one — the inevitable consequence of a world that never held them accountable.
Madison Area Lyme Support Group 